Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Enhanced hype.

David G Harrison1, W Virgil Brown, Paolo Raggi

  • 1Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. dharr02@emory.edu

The American Journal of Cardiology
|July 22, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monocyte Oxidative Stress Underlies Persistent Immune Activation in Long COVID Postural Orthostatic Tachycardia Syndrome.

medRxiv : the preprint server for health sciences·2026
Same author

Brush border intermicrovillar adhesion limits bacteria attachment to the small intestine brush border.

bioRxiv : the preprint server for biology·2026
Same author

Hypertension as an Immune Disorder: From Cellular Drivers to Molecular Mediators.

Immunological reviews·2026
Same author

Research Letters and Editorials in Hypertension.

Hypertension (Dallas, Tex. : 1979)·2025
Same author

Hypertension Editors' View of the 2025 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.

Hypertension (Dallas, Tex. : 1979)·2025
Same author

Hypertension promotes bone loss and fragility by favoring bone resorption in mouse models.

The Journal of clinical investigation·2025
Same journal

Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

The American journal of cardiology·2026
Same journal

ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

The American journal of cardiology·2026
Same journal

Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

The American journal of cardiology·2026
Same journal

Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026
Same journal

Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

The American journal of cardiology·2026
Same journal

Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2026
See all related articles

The ENHANCE trial, studying ezetimibe and simvastatin for familial hypercholesterolemia, did not invalidate lipid-lowering benefits. Further analysis is needed before concluding against vascular disease prevention through lipid modification.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Familial hypercholesterolemia (FH) is a genetic disorder leading to high LDL cholesterol.
  • Vascular disease prevention is a major focus in cardiovascular medicine.
  • The ENHANCE trial investigated a specific lipid-lowering combination therapy.

Purpose of the Study:

  • To evaluate the effect of combination ezetimibe and high-dose simvastatin versus simvastatin alone on the atherosclerotic process.
  • To critically analyze the ENHANCE trial's design, patient population, and surrogate endpoint.
  • To contextualize the ENHANCE trial findings within the broader evidence base for lipid-lowering therapies.

Main Methods:

  • Analysis of the Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients With Heterozygous Familial Hypercholesterolemia (ENHANCE) trial.

Related Experiment Videos

  • Review of trial subjects and the surrogate endpoint utilized.
  • Comparison of ENHANCE results with existing literature on lipid-lowering interventions.

    • Main Results:

    • The ENHANCE trial's results have been interpreted by some as questioning the efficacy of lipid lowering.
    • A detailed examination of the trial's specifics is necessary for accurate interpretation.
    • The study highlights the importance of considering the full body of evidence.

    Conclusions:

    • The ENHANCE trial should not be the sole basis for refuting the benefits of lipid lowering in vascular disease.
    • Lipid lowering through various approaches has demonstrated benefits in numerous studies.
    • Public and physician reactions to the ENHANCE trial have been disproportionate and should be tempered with scientific rigor.